Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403709 | 0.88 | TNF (0.49) | MAPTNPY5RTDP1FFAR4PRMT5 | |
| SCHEMBL8029435 | 0.87 | ATM (0.53) | ALDH1A1KDM4ENPY5RKMT2ATSHR | |
| SCHEMBL27844158 | 0.84 | NPY5R (0.45) | ALDH1A1KDM4ENPY5RKMT2ATSHR | |
| SCHEMBL4335712 | 0.83 | TNF (0.51) | FFAR4RORC | |
| SCHEMBL3689068 | 0.81 | F2 (0.45) | MAPTALDH1A1KDM4EKMT2AHSD17B10 | |
| SCHEMBL30396580 | 0.81 | F2 (0.45) | MAPTALDH1A1KDM4EKMT2AHSD17B10 | |
| SCHEMBL3465527 | 0.81 | KMT2A (0.55) | ALDH1A1KDM4ENPY5RKMT2ATSHR | |
| SCHEMBL20037218 | 0.80 | TDP1 (0.53) | MAPTALDH1A1NPY5RKMT2ATSHR | |
| SCHEMBL4483940 | 0.80 | ATM (0.43) | MAPTALDH1A1KDM4EKMT2AHSD17B10 | |
| SCHEMBL1666483 | 0.80 | NTSR1 (0.52) | MAPTALDH1A1HPGDPOLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| CN-102264731-A | 1, 2, 4 -oxadiazole derivatives and their therapeutic use | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | MAPT 3569/4885ALDH1A1 1042/4885KDM4E 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.